Sec Form 5 Filing - Bassaganya-Riera Josep @ Landos Biopharma, Inc. - 2021-12-31

FORM 5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Bassaganya-Riera Josep 2. Issuer Name and Ticker or Trading Symbol Landos Biopharma, Inc. [ LABP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O BIOTHERAPEUTICS INC, 1800 KRAFT DR, SUITE 100 3. Date of Earliest Transaction (MM/DD/YY) 12/31/2021 (Street) BLACKSBURG, VA24060 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price common stock 12/28/2021 G V 1,000,000( 1 ) D $ 0 3,994,208 I by trust( 2 ) common stock 766,405 I by GRAT( 3 ) common stock 823,956 I by GRAT( 4 ) common stock 786,299 I by family trust( 5 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr . 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Bassaganya-Riera Josep C/O BIOTHERAPEUTICS INC, 1800 KRAFT DR SUITE 100 BLACKSBURG, VA24060 X Signatures Josep Bassaganya-Riera 02/14/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These shares were gifted to a charitable remainder unitrust. ( 2 )These shares are held by the Josep Bassaganya-Riera Revocable Trust dated April 9, 2018, as amended (the "2018 Trust"). The Reporting Person is the sole trustee of the 2018 Trust and the beneficiaries are the Reporting Person's immediate family members. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. ( 3 )These shares are held by the Josep Bassaganya-Riera Grantor Retained Annuity Trust No. 1 dated June 28, 2018 (the "2018 GRAT"). The Reporting Person is the sole trustee of the 2018 GRAT and the beneficiaries are the Reporting Person's immediate family members. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. ( 4 )These shares are held by the Josep Bassaganya-Riera Grantor Retained Annuity Trust No. 2 dated March 26, 2019 (the "2019 GRAT"). The Reporting Person is the sole trustee or the 2019 GRAT and the beneficiaries are the Reporting Person's immediate family members. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. ( 5 )These shares are held by the Raquel Hontecillas-Magarzo Irrevocable Family Trust dated October 1, 2021 (the "2021 Family Trust"). The Reporting Person is the sole trustee of the 2021 Family Trust and the beneficiaries are the Reporting Person and the Reporting Person's immediate family members. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.